program discusses the incidence and implications of acute kidney injury (AKI),
including new biomarkers that can predict patient risk for AKI, which could
allow physicians to intervene and potentially avoid the morbidity and mortality
associated with the condition. Also discussed are heart failure biomarkers and
their advantages and limitations in heart failure patients being treated with
the new heart failure drug ENTRESTO.
the importance of early diagnosis of acute kidney injury.
relevant biomarkers and a new diagnostic tool for predicting acute kidney
strategies that can be used to enhance a laboratory's value in diagnosing acute
biomarkers used in heart failure assessment, and the strengths and limitations
of each biomarker.